Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

927 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis.
Saliba RM, Alousi AM, Pidala J, Arora M, Spellman SR, Hemmer MT, Wang T, Abboud C, Ahmed S, Antin JH, Beitinjaneh A, Buchbinder D, Byrne M, Cahn JY, Choe H, Hanna R, Hematti P, Kamble RT, Kitko CL, Laughlin M, Lekakis L, MacMillan ML, Martino R, Mehta PA, Nishihori T, Patel SS, Perales MA, Rangarajan HG, Ringdén O, Rosenthal J, Savani BN, Schultz KR, Seo S, Teshima T, van der Poel M, Verdonck LF, Weisdorf D, Wirk B, Yared JA, Schriber J, Champlin RE, Ciurea SO. Saliba RM, et al. Among authors: martino r. Transplant Cell Ther. 2022 Oct;28(10):681-693. doi: 10.1016/j.jtct.2022.07.013. Epub 2022 Jul 16. Transplant Cell Ther. 2022. PMID: 35853610 Free PMC article.
Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes.
Martino R, Caballero MD, Pérez-Simón JA, Canals C, Solano C, Urbano-Ispízua A, Bargay J, Léon A, Sarrá J, Sanz GF, Moraleda JM, Brunet S, San Miguel J, Sierra J; AML and alloPBSCT Subcommittees of the Spanish Group for Hematopoietic Transplantation. Martino R, et al. Blood. 2002 Sep 15;100(6):2243-5. doi: 10.1182/blood-2002-02-0400. Blood. 2002. PMID: 12200391 Free article. Clinical Trial.
Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.
Kröger N, Perez-Simon JA, Myint H, Klingemann H, Shimoni A, Nagler A, Martino R, Alegre A, Tomas JF, Schwerdtfeger R, Kiehl M, Fauser A, Sayer HG, Leon A, Beyer J, Zabelina T, Ayuk F, San Miguel JF, Brand R, Zander AR. Kröger N, et al. Among authors: martino r. Biol Blood Marrow Transplant. 2004 Oct;10(10):698-708. doi: 10.1016/j.bbmt.2004.06.002. Biol Blood Marrow Transplant. 2004. PMID: 15389436 Free article. Clinical Trial.
Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation.
Khoury HJ, Loberiza FR Jr, Ringdén O, Barrett AJ, Bolwell BJ, Cahn JY, Champlin RE, Gale RP, Hale GA, Urbano-Ispizua A, Martino R, McCarthy PL, Tiberghien P, Verdonck LF, Horowitz MM. Khoury HJ, et al. Among authors: martino r. Blood. 2006 Feb 15;107(4):1712-6. doi: 10.1182/blood-2005-07-2661. Epub 2005 Oct 20. Blood. 2006. PMID: 16239431 Free PMC article.
Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D, Martino R, Caballero D, Martin J, Ferra C, Nieto JB, Sampol A, Bernal MT, Piñana JL, Vazquez L, Ribera JM, Besalduch J, Moraleda JM, Carrera D, Brunet MS, Perez-Simón JA, Sierra J. Valcárcel D, et al. Among authors: martino r. J Clin Oncol. 2008 Feb 1;26(4):577-84. doi: 10.1200/JCO.2007.11.1641. Epub 2007 Dec 17. J Clin Oncol. 2008. PMID: 18086801
The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia.
Delgado J, Pillai S, Benjamin R, Caballero D, Martino R, Nathwani A, Lovell R, Thomson K, Perez-Simon JA, Sureda A, Kottaridis P, Vazquez L, Peggs K, Sierra J, Milligan D, Mackinnon S. Delgado J, et al. Among authors: martino r. Biol Blood Marrow Transplant. 2008 Nov;14(11):1288-97. doi: 10.1016/j.bbmt.2008.09.001. Biol Blood Marrow Transplant. 2008. PMID: 18940684 Free article.
Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC.
Barba P, Piñana JL, Martino R, Valcárcel D, Amorós A, Sureda A, Briones J, Delgado J, Brunet S, Sierra J. Barba P, et al. Among authors: martino r. Biol Blood Marrow Transplant. 2010 Mar;16(3):413-20. doi: 10.1016/j.bbmt.2009.11.008. Epub 2009 Nov 14. Biol Blood Marrow Transplant. 2010. PMID: 19922807 Free article.
927 results